Candida vulvovaginitis natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Dima Nimri, M.D. [2], Aravind Kuchkuntla, M.B.B.S [3]

Overview

Candida vulvovaginitis is a self limiting disease with no complications. Candida vulvovaginitis is very responsive to local or oral antifungals.

Natural History, Complications and Prognosis

Natural History

Candida vulvovaginitis is a common infection of women in reproductive age group. Patients present with vulvar pruritus, dysuria, and vaginal discharge. Half of the affected patients have multiple episodes of the infection and less than 10% have recurrent infection.^[1]

Prognosis

Candida albicans vulvovaginitis has excellent prognosis with azole therapy. Patients with non-Candida albicans infections are prone to have recurrence and treatment with boric acid and oral fluconazole has good prognosis.^[2]

Complications

Candida vulvovaginitis is a self limiting disease with no complications.

References

↑ Fidel PL, Vazquez JA, Sobel JD (1999). “Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans”. Clin Microbiol Rev. 12 (1): 80–96. PMC 88907. PMID 9880475.
↑ Fidel PL, Vazquez JA, Sobel JD (1999). “Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans”. Clin Microbiol Rev. 12 (1): 80–96. PMC 88907. PMID 9880475.

Template:WH Template:WS

[pmid98804752-1] Fidel PL, Vazquez JA, Sobel JD (1999). “Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans”. Clin Microbiol Rev. 12 (1): 80–96. PMC 88907. PMID 9880475.

[pmid98804753-2] Fidel PL, Vazquez JA, Sobel JD (1999). “Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans”. Clin Microbiol Rev. 12 (1): 80–96. PMC 88907. PMID 9880475.

[1]

[2]